Sign inJoin waitlistJoin the waitlist

Craig Cole

Core Faculty · McLaren Health Care Corporation

Credentials: · · · ·

History

McLaren Health Care Corporation
Present

Medical Oncology
1999–2001
Hematology
1998–1999
Internal Medicine
1995–1998
Ohio State University College of Medicine
1991–1995

Research

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
New England Journal of Medicine · 2019 · 537 citations
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma
Journal of Clinical Oncology · 2008 · 334 citations
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma
Journal of Clinical Oncology · 2009 · 224 citations

Jeffrey Zonder
5 papers
Joseph Mikhael
5 papers
Ravi Vij
5 papers
Ajai Chari
4 papers
Ajay Nooka
4 papers
Hearn Cho
4 papers
RJ
Russell Jacoby
4 papers
AY
Andrew Yee
3 papers
AJ
Andrzej Jakubowiak
3 papers
Joshua Richter
3 papers
Ken Anderson
3 papers
AS
Alexander Stewart
2 papers

Clinical trials

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Site PI · Recruiting · Phase 3
GlaxoSmithKline
2024–2031
DapagliFLOzin in Renal AL Amyloidosis (FLORAL)
Sub-investigator · Recruiting · Phase 2
Barbara Ann Karmanos Cancer Institute
2024–2028
Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
Sub-investigator · Recruiting · Phase 2
Barbara Ann Karmanos Cancer Institute
2023–2028